HLA-Mismatched Allogeneic Cellular Therapy (Microtransplantation) After Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia < 60 Years

This phase II trial studies how well donor cellular therapy after cytarabine works in treating patients with intermediate-risk acute myeloid leukemia with a decrease in or disappearance of signs and symptoms of cancer. Donor cellular therapy is a short-term transfusion of cells from a family member who is incompletely matched. The use of these partially matched white blood cells may help improve response to standard chemotherapy (cytarabine) and reduce some of the risks of infection, without a permanent transplant. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving donor cellular therapy after cytarabine may kill more cancer cells.

Start Date12 Dec 2018

Sponsor / Collaborator

University of Southern California

[+1]

NCT01871441 / TerminatedPhase 2IIT

A Two Step Approach to Haploidentical Hematopoietic Stem Cell Transplantation for Patients in Remission From HLA Partially-Matched Related Donors-Effect of Maternal Donors on Outcomes

This phase II trial studies how well haploidentical donor hematopoietic stem cell transplant works in treating patients with hematologic malignancies. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. Giving an infusion of the donor's T cells (donor lymphocyte infusion) may replace the patient's immune cells and help destroy any remaining cancer cells. When the stem cells from a related donor, that closely matches the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.

Start Date17 May 2013

Sponsor / Collaborator

Sidney Kimmel Cancer Center at Thomas Jefferson University

NCT01839916 / CompletedPhase 2IIT

Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies

This pilot phase II trial studies how well giving donor T cells after donor stem cell transplant works in treating patients with hematologic malignancies. In a donor stem cell transplant, the donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect.

Start Date04 Apr 2013

Sponsor / Collaborator

The University of Chicago

[+1]

100 Clinical Results associated with Allogeneic lymphocytes(Sidney Kimmel Cancer Center at Thomas Jefferson University)

100 Translational Medicine associated with Allogeneic lymphocytes(Sidney Kimmel Cancer Center at Thomas Jefferson University)

100 Patents (Medical) associated with Allogeneic lymphocytes(Sidney Kimmel Cancer Center at Thomas Jefferson University)

100 Deals associated with Allogeneic lymphocytes(Sidney Kimmel Cancer Center at Thomas Jefferson University)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adult Acute Myeloblastic Leukemia	Phase 2	US	Sidney Kimmel Cancer Center at Thomas Jefferson University	24 Dec 2012
Adult Lymphoblastic Lymphoma	Phase 2	US	Sidney Kimmel Cancer Center at Thomas Jefferson University	24 Dec 2012
Adult T-Cell Leukemia-Lymphoma	Phase 2	US	Sidney Kimmel Cancer Center at Thomas Jefferson University	24 Dec 2012
Aggressive-Phase Chronic Myelocytic Leukemia	Phase 2	US	Sidney Kimmel Cancer Center at Thomas Jefferson University	24 Dec 2012
Anaplastic Large-Cell Lymphoma	Phase 2	US	Sidney Kimmel Cancer Center at Thomas Jefferson University	24 Dec 2012
Anemia, Refractory, With Excess of Blasts	Phase 2	US	Sidney Kimmel Cancer Center at Thomas Jefferson University	24 Dec 2012
Blast Phase Chronic Granulocytic Leukemia	Phase 2	US	Sidney Kimmel Cancer Center at Thomas Jefferson University	24 Dec 2012
Burkitt Lymphoma	Phase 2	US	Sidney Kimmel Cancer Center at Thomas Jefferson University	24 Dec 2012
Chronic Lymphocytic Leukemia	Phase 2	US	Sidney Kimmel Cancer Center at Thomas Jefferson University	24 Dec 2012
Chronic Myelomonocytic Leukemia	Phase 2	US	Sidney Kimmel Cancer Center at Thomas Jefferson University	24 Dec 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01839916 (CTgov)	Phase 2	Marginal zone lymphoma recurrent \| Recurrent Adult Grade III Lymphomatoid Granulomatosis \| Burkitt Lymphoma ... View more	77	laboratory biomarker analysis+therapeutic allogeneic lymphocytes	ldqonqreln(surmypqoor) = zkonudhiyh ynytnooeqt (jzzxxxezxe, puiamfzeeb - iigkqojusc) View more	-	07 Aug 2019
NCT01871441 (CTgov)	Phase 2	Hematologic Neoplasms	4	Allogeneic hematopoietic stem cell transplantation (HSCT)+Cyclophosphamide+Donor lymphocytes infusion (DLI)+Tacrolimus+mycophenolate mofetil	xryryuxazc(gzvjzlfvfs) = ifnbnndgre slazrymiss (vpwhherawm, poxwhkngia - rxmwssdinb) View more	-	09 Jan 2018
NCT00245037 (CTgov)	Phase 1/2	Myelodysplastic-Myeloproliferative Diseases \| Multiple Myeloma \| Myeloproliferative Disorders ... View more	147	peripheral blood stem cell transplantation+cyclosporine+fludarabine phosphate+Busulfan+therapeutic allogeneic lymphocytes+mycophenolate mofetil+methotrexate+Phenytoin	umrhosqofl(crrbzvwpbw) = csdcongorg jbdurmgmyp (dodaxbtmdn, lifbrmeqll - ymhnsqkacv) View more	-	02 Jul 2017
NCT01118013 (CTgov)	Phase 2	Myelodysplastic-Myeloproliferative Diseases \| Plasma Cell Neoplasms \| Multiple Myeloma ... View more	6	allogeneic hematopoietic stem cell transplantation+fludarabine phosphate+Busulfan+therapeutic allogeneic lymphocytes+Filgrastim+Tacrolimus+mycophenolate mofetil+Methotrexate	amivszgotl(hckjbobhdv) = zkndfbiywr tmthtkddjs (kkudcxnloy, tdfubvmukn - chmpmmkgsf) View more	-	24 Mar 2017
NCT00068718 (CTgov)	Phase 1/2	Recurrent Multiple Myeloma \| Acute Myeloid Leukemia \| Recurrent Adult Acute Lymphoblastic Leukemia ... View more	35	Therapeutic Allogeneic Lymphocytes	ftmapuwjgm(rqvzbhnlfe) = bzvnfktjsw gtzuvwbegr (xvavqxktcm, ysdusdnmjt - dcdtffrppb) View more	-	10 Mar 2017
NCT00074269 (CTgov)	Phase 2	Metastatic breast cancer	5	Anti-Thymocyte Globulin+cyclosporine+fludarabine phosphate+therapeutic allogeneic lymphocytes+melphalan+Filgrastim+methotrexate	xtfmgbqpxo(ojvzloorzz) = sjjtyjmzpe ciqenyhxol (qbkuuzxdpk, jkwieyyzpe - jaffigjlir) View more	-	24 Nov 2014
NCT00176501 (CTgov)	Phase 2	Renal Cell Carcinoma	3	therapeutic allogeneic lymphocytes	jqhjbqvfmp(uqlddaawso) = irvztbqnvn pnnsnkllpx (csnelvwybm, ghxomctrgz - vkwxcrsnxd) View more	-	06 Jan 2014

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis